26 Aug 2024 – EyRIS is thrilled to announce our strategic partnership with @i-Cognitio Sciences (i-cog), a pioneering Hong Kong-based company, to integrate their cutting-edge RetinAD technology into our EySCAN platform. This collaboration represents a major leap forward in non-invasive brain health assessments and early detection of Alzheimer’s risk.
RetinAD is an AI-powered tool that analyzes retinal images to deliver rapid, non-invasive brain health assessments within seconds. Powered by sophisticated AI algorithms and a diverse gold-standard dataset, RetinAD effectively distinguishes between Alzheimer’s dementia and cognitively normal subjects, identifying individuals at risk and enabling timely interventions. This approach complements more invasive and costly methods like blood tests or brain scans, making RetinAD ideal for mass screening.
In the coming months, this transformative technology will be seamlessly integrated into our EySCANplatform, enhancing our suite of offerings. By making early Alzheimer’s risk assessment more accessible and affordable, we aim to improve the quality of life for millions worldwide.
About EyRIS
EyRIS is dedicated to revolutionizing
healthcare delivery through AI-powered solutions, aiming to be a game-changer in first-stage medical diagnostics. Our innovative products for detecting retinal and chronic diseases are now deployed in population screening programs across three Ministries of Health in Asia and the Middle East, with a presence in over 30 countries.
About i-Cognitio Sciences
i-Cog is at the forefront of medical technology, revolutionizing disease diagnostics and management. The i-Cog team is committed to advancing the early detection and treatment of neurodegenerative and retinal diseases through cutting-edge ocular imaging and AI technologies. We aspire to become the global leader in non-invasive diagnostic solutions, significantly improving patient outcomes and healthcare efficiency worldwide.
For media inquiries, please contact steven.ang@nova-hub.com
Comments are closed.